NA-LND-GC
Optimizing the Extent of Lymph Node Dissection After Neoadjuvant Therapy for Gastric and Esophagogastric Junction Adenocarcinoma: A Multicenter Retrospective Cohort Study
Sponsor study identifier
observational
2,000
1 country
8
Study Start
October 25, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
December 31, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
February 27, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
This multicenter retrospective observational cohort study will evaluate approximately 2,000 adults with gastric or esophagogastric junction adenocarcinoma who received at least two cycles of neoadjuvant therapy followed by R0 gastrectomy with lymph node dissection. The study will estimate the frequency of pathological metastasis at individual lymph node stations according to the final preoperative imaging-based ycT and ycN categories and tumor location. The findings are intended to provide evidence for future prospective studies of risk-adapted reduction of perigastric lymph node dissection. No treatment is assigned by this study.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
February 27, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 22, 2026
Actual (reported)October 25, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
October 29, 2026
Actual (reported)December 31, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
February 27, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Station-specific lymph node metastasis rates stratified by ycT and ycN categories
For each E, U, M, and L tumor-location cohort and each prespecified lymph node station, the metastasis rate will be calculated as the number of patients with pathologically confirmed metastasis at that station divided by the number of patients in whom that station was actually dissected and had an evaluable station-specific pathological record. Rates will be reported across the complete AJCC/UICC eighth-edition ycT and ycN categories. Stations not dissected or not verifiably recorded will be excluded from the station-specific denominator and will not be classified as negative.
At definitive postoperative pathological assessment, generally within 30 days after gastrectomy
Station-specific lymph node metastasis rates stratified by ypT, ypN, and tumor regression grade
At definitive postoperative pathological assessment, generally within 30 days after gastrectomy
Patients with tumors whose upper margin reaches or crosses the esophagogastric junction, or whose endoscopy report explicitly describes an unclear, immediately adjacent, or involved dentate line.
Patients with non-E tumors centered in the upper third of the stomach according to the Japanese Gastric Cancer Association anatomical classification.
Patients with non-E tumors centered in the middle third of the stomach according to the Japanese Gastric Cancer Association anatomical classification.
Patients with non-E tumors centered in the lower third of the stomach according to the Japanese Gastric Cancer Association anatomical classification.
Adults treated at participating tertiary hospitals in China who underwent surgery from January 1, 2021, through August 30, 2026, for histologically confirmed gastric or esophagogastric junction adenocarcinoma after neoadjuvant therapy.
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
The First People's Hospital of Lianyungang
Lianyungang, Jiangsu, China
Affiliated Drum Tower Hospital, Medical School of Nanjing University
Nanjing, Jiangsu, China
Jiangsu Cancer Hospital
Nanjing, Jiangsu, China
The First Affiliated Hospital with Nanjing Medical University
Nanjing, Jiangsu, China
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
The Affiliated Hospital of Qingdao University
Hao Xu, MD, PhD
The First Affiliated Hospital with Nanjing Medical University
First Submitted
October 22, 2026
First Posted
October 29, 2026
Study Start
October 25, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
December 31, 2026
Numbers of examined and metastatic lymph nodes according to tumor location
At definitive postoperative pathological assessment, generally within 30 days after gastrectomy
Contact the study team to confirm eligibility.
Qingdao, Shandong, China
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
February 27, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
October 29, 2026
Record last verified: 2026-10
Due to the ethic requirements of multicentered study.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: